About Immunitybio (IBRX)
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the ... Read more
- USD5.11
- USD7.74
- USD4.92
- USD7.74
- 43.60%
- 1M
- 446.32k
- 7.39M
- 5.0B
- 1.25
- 225.20%
Stock News
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
